Logunov, Denis Y
Dolzhikova, Inna V
Zubkova, Olga V
Tukhvatulin, Amir I
Shcheblyakov, Dmitry V
Dzharullaeva, Alina S
Grousova, Daria M
Erokhova, Alina S
Kovyrshina, Anna V
Botikov, Andrei G
Izhaeva, Fatima M
Popova, Olga
Ozharovskaya, Tatiana A
Esmagambetov, Ilias B
Favorskaya, Irina A
Zrelkin, Denis I
Voronina, Daria V
Shcherbinin, Dmitry N
Semikhin, Alexander S
Simakova, Yana V
Tokarskaya, Elizaveta A
Lubenets, Nadezhda L
Egorova, Daria A
Shmarov, Maksim M
Nikitenko, Natalia A
Morozova, Lola F
Smolyarchuk, Elena A
Kryukov, Evgeny V
Babira, Vladimir F
Borisevich, Sergei V
Naroditsky, Boris S
Gintsburg, Alexander L
This article is maintained by: Elsevier
Article Title: Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia
Journal Title: The Lancet
CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/S0140-6736(20)31866-3
CrossRef DOI link to the associated document: https://doi.org/10.1016/S0140-6736(20)31867-5
Content Type: article
Copyright: © 2020 Elsevier Ltd. All rights reserved.